We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.02% | 65.55 | 65.55 | 66.00 | 66.14 | 65.16 | 65.43 | 7,318,161 | 01:00:00 |
From May 2019 to May 2024
By Dominic Chopping
STOCKHOLM--Swedish pharmaceutical company Vicore Pharma Holding AB said Monday that data from a phase II study of its C21 drug suggests that, when used in conjunction with corticosteroids and remdesivir, the drug can restore lung function in Covid-19 patients.
Vicore Pharma's C21 drug is used to treat lung disease idiopathic pulmonary fibrosis.
The company said the study suggests that C21 can become an important complement to vaccines to combat the Covid-19 pandemic.
"The complete analysis confirms the initial observation that C21 is safe, restores lung function and reduces the need for oxygen supplementation in these critically ill Covid-19 patients," said Chief Executive Carl-Johan Dalsgaard.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
February 01, 2021 02:34 ET (07:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
